-
Cantor Fitzgerald Reiterates Neutral Rating on LeMaitre Vascular (LMAT)
-
Lemaitre Vascular (LMAT) Tops Q3 EPS by 5c ; Offers Guidance
-
Cantor Fitzgerald Reiterates Neutral Rating on LeMaitre Vascular (LMAT)
-
Barrington Research Upgrades LeMaitre Vascular (LMAT) to Outperform
-
Lemaitre Vascular (LMAT) Tops Q2 EPS by 3c
-
Citizens JMP Reiterates Market Outperform Rating on LeMaitre Vascular (LMAT)
-
Lemaitre Vascular (LMAT) Misses Q1 EPS by 3c, Beats on Revenue; Offers FY25 Guidance
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Barrington Research Downgrades LeMaitre Vascular (LMAT) to Market Perform
-
Oppenheimer Downgrades LeMaitre Vascular (LMAT) to Perform
-
LeMaitre Vascular (LMAT) PT Raised to $113 at Citizens JMP
-
Lemaitre Vascular (LMAT) Tops Q4 EPS by 3c, Beats on Revenue; Offers FY25 Guidance
-
LeMaitre Vascular (LMAT) names Dorian LeBlanc as new CFO
-
Wells Fargo Starts LeMaitre Vascular (LMAT) at Equal Weight
-
Lemaitre Vascular (LMAT) Announces Proposed $150M Convertible Notes Offering
-
LeMaitre Vascular (LMAT) PT Raised to $93 at Oppenheimer
-
LeMaitre Vascular (LMAT) PT Raised to $100 at Stifel
-
Lemaitre Vascular (LMAT) Tops Q3 EPS by 5c
-
Cantor Fitzgerald Starts LeMaitre Vascular (LMAT) at Neutral
-
Lemaitre Vascular (LMAT) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY24 Guidance

